# TherapeuticsMD, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [TherapeuticsMD, Inc.](/companies/txmd.md) (CIK 25743)
- Form: 10-Q
- Filed: 2022-11-14
- Accepted by EDGAR: Nov 14, 2022, 17:03 ET
- Period: 2022-09-30
- Accession: 0001564590-22-037666
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/25743/000156459022037666/txmd-10q_20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/25743/000156459022037666/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $20.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $68.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-07-01 to 2022-09-30 | $3.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-01-01 to 2022-09-30 | $13.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-07-01 to 2022-09-30 | $17.1m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-01 to 2022-09-30 | $55.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | −$20.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | −$65.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-07-01 to 2022-09-30 | $4.8m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-01-01 to 2022-09-30 | $30.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | −$260.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $290.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | −$29.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $34.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | −$3.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $3.73 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | −$3.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $3.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 9,261,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 9,205,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$63.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $21.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $27.1m | us-gaap:Cash |
| Current assets | at 2022-09-30 | $87.5m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $133.9m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $174.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $182.2m | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $93.6m | us-gaap:LongTermDebt |
| Current portion of debt | at 2022-09-30 | $93.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-09-30 | −$48.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 50,300 characters.

The following discussion should be read in conjunction with our 2021 Annual Report on Form 10-K (“2021 10-K Report”), and the consolidated financial statements and related notes in Item 1, Financial Statements, appearing elsewhere in this this Quarterly Report on Form 10-Q (“10-Q Report”). The following discussion may contain forward-looking statements, and our actual results may differ materially from the results suggested by these forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of our 2021 10-K Report under the heading “Risk Factors,” as updated and supplemented by Part II, Item 1A of this 10-Q Report. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Certain amounts in the following discussion may not add due to rounding, and all percentages have been calculated using unrounded amounts.

### Forward-looking statements

This 10-Q Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, debt position, liquidity, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, cost reduction strategies, research and development (“R&D”), marketing, expenses and sales are all forward-looking statements. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect,” or the negative of such terms or other comparable terminology.

We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date of this 10-Q Report, and but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments, except as required by law or by the rules and regulations of the SEC.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Factors that could cause or contribute to such differences include, but are not limited to, our liquidity requirements, supply chain issues, management transitions, risks related to the Financing Agreement, market and general economic factors, and the other risks discussed in Part I, Item 1A of our 2021 10-K Report, as updated and supplemented by Part II, Item 1A of this 10-Q Report.

### Business overview

We are a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women’s healthcare focus.

### vitaCare Divestiture

On April 14, 2022, we completed the divestiture of vitaCare Prescription Services, Inc. (“vitaCare”) with the sale of all of vitaCare’s issued and outstanding capital stock (the “vitaCare Divestiture”). We received net proceeds of $142.6 million, net of transaction costs of $7.2 million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary holdbacks as provided in the stock purchase agreement (the “Purchase Agreement”), which is recorded as restricted cash in the consolidated balance sheets. The restricted cash is held by an escrow agent and will be released to us in April 2023 upon a joint written direction from the buyer and us being delivered to the escrow agent to disburse to us an amount equal to the amount of escrow funds less any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement. Any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement shall be retained by the escrow agent until each such claim subject thereto is resolved. Additionally, we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare’s financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement. We will record the contingent consideration at the settlement amount when the consideration is realized or realizable.

The Purchase Agreement contains customary representations and warranties, covenants and indemnities of the parties thereto. In addition, upon closing of the vitaCare Divestiture, (i) we entered into a long-term services agreement with vitaCare to continue utilization of the vitaCare platform with respect to our products, and (ii) we entered into a transition services agreement with vitaCare for us to provide certain transition services to vitaCare for up to 12 months following the closing.

### COVID-19

With multiple variant strains of the SARS-Cov-2 virus and the COVID-19 disease that it causes (collectively, “COVID-19”) still circulating, we continue to be subject to risks and uncertainties in connection with the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. The ultimate global recovery from the pandemic will be dependent on, among other things, actions taken by governments and businesses to contain and combat the virus, including any variant strains, the speed and effectiveness of vaccine production and global distribution, as well as how quickly, and to what extent, normal economic and operating conditions can resume on a sustainable basis globally.

Since the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. We have also partnered with independent community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause which provide patients real-time access to both diagnosis and treatment. We continue to support prescribers’ needs with samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity plans and infrastructure in place that allows for live virtual e-detailing of our products.

As part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses and implemented cost saving measures, which included negotiating lower fees or suspending services from third-party vendors; implementing a company-wide hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event expenses. In addition, we implemented a significant cost savings initiative that was designed to reduce our annual operating costs in 2022, and we reduced the operating costs of the vitaCare business with the completion of the vitaCare Divestiture on April 14, 2022. See above for additional information regarding the vitaCare Divestiture.

The full impact of the COVID-19 pandemic continues to evolve. As of the date of issuance of these consolidated financial statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity, or results of operations remains uncertain. We are continuing to assess the effect of the COVID-19 pandemic on our operations by monitoring the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future.

While we currently believe that our COVID-19 contingency plan has the ability to mitigate many of the negative effects of the COVID-19 pandemic on our business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, the duration of “social distancing” orders, the ability of our sales force to access healthcare providers to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which remain uncertain. Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that we may face.

### Going concern

We incurred a loss from operations of $65.8 million and interest expense and other financing costs of $30.9 million during the nine months ended September 30, 2022, and as of that date, our current liabilities exceeded our current assets by $86.6 million and our total liabilities exceeded our total assets by $48.3 million. We will need to raise additional capital to repay the entire principal balance of the Financing Agreement, dated as of April 24, 2019, as amended (the “Financing Agreement”), with Sixth Street Specialty Lending, Inc., as administrative agent (the “Administrative Agent” or “Sixth Street”), various lenders from time to time party thereto (the “Lenders”), and certain of our subsidiaries party thereto from time to time as guarantors, and to provide additional liquidity to fund our losses until our operations become cash flow positive.

On July 29, 2022, we closed on a private placement offering with Rubric Capital Management LP (the “Preferred Stock Investor”), pursuant to which we issued and sold (i) 15,000 shares of the Company’s newly-designated Series A Preferred Stock, par value $0.001 per share (“Preferred Stock”) and (ii) 565,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and we received aggregate gross proceeds of $15.0 million, before expenses.

On July 29, 2022, we entered into Amendment No. 16 to the Financing Agreement pursuant to which the maturity date of the Financing Agreement was extended to September 30, 2022, with the Company having the option to further extend the maturity date to October 31, 2022, and November 30, 2022, in each case if the Company receives not less than $7.0 million in cash proceeds from an equity issuance, which, if preferred equity, is on substantially the same terms as the Preferred Stock. In connection with the closing of a private placement offering with the Preferred Stock Investor on September 30, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on September 30, 2022, the maturity date of the Financing Agreement was extended to October 31, 2022. In connection with the closing of a private placement offering with the Preferred Stock Investor on October 28, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on October 28, 2022 the maturity date of the Financing Agreement was extended to November 30, 2022.

On September 30, 2022, we closed on an additional private placement offering with the Preferred Stock Investor, pursuant to which we issued and sold 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the maturity date of the Preferred Stock of December 31, 2022, which shall be automatically extended, on a day-for-day basis, to the extent the maturity date under the Financing Agreement is extended, but by no more than a total of 60 days without the consent of the holders representing at least 66 2/3% of the outstanding shares of Preferred Stock (the “Preferred Stock Maturity Date”) or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment. See Note 10, Mandatory Redeemable Preferred Stock and Stockholders’ Deficit for additional information regarding the equity financing with the Preferred Stock Investor.

In connection with the closing of the private placement offering with the Preferred Stock Investor on September 30, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on September 30, 2022, we issued warrants (“Lender Warrants”) to the Lenders to purchase an aggregate of 125,000 shares of Common Stock and the maturity date of the Financing Agreement was extended to October 31, 2022. The Lender Warrants have an exercise price of $0.01 per share of Common Stock, subject to certain adjustment as provided therein, and an expiration date of September 30, 2032. The Lender Warrants may also be exercised via cashless exercise pursuant to the terms thereof.

On October 28, 2022, we closed on an additional private placement offering with the Preferred Stock Investor, pursuant to which we issued and sold 7,000 shares of the Company’s Preferred Stock for an aggregate offering price of $7.0 million. In addition, in lieu of issuing, selling and delivering 263,666 shares of Common Stock to the Preferred Stock Investor, we agreed to pay the Preferred Stock Investor, on the later of (i) the Preferred Stock Maturity Date or (ii) the date our obligations under the Financing Agreement are paid in full, a make-whole payment equal to 263,666 multiplied by the closing price of our Common Stock on the principal securities exchange or securities market on which the Common Stock is then traded, on the day prior to the date of payment of the make-whole payment.

In connection with the closing of the private placement offering with the Preferred Stock Investor on October 28, 2022, and in accordance with Amendment No. 16 to the Financing Agreement, on October 28, 2022, we issued Lender Warrants to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement and the maturity date of the Financing Agreement was extended to November 30, 2022. See Note 16, Subsequent Events for additional information regarding amendments to the Financing Agreement.

To address our capital needs, we are pursuing various equity and debt refinancing and other strategic alternatives, including the possibility that we will file for Chapter 11 protection if our equity and debt refinancing or other strategic alternatives fail prior to the maturity date of our Financing Agreement. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares. To the extent that we raise additional capital through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us. Along with considering additional financings and other strategic alternatives, we have reviewed numerous potential scenarios in connection with steps that we may take to reduce our operating expenses.

If we are unsuccessful with future financings, if the successful commercialization of ANNOVERA, IMVEXXY, or BIJUVA is delayed, or if the continued impact of the COVID-19 pandemic or issues in our supply chains related to our third-party contract manufacturers on our business is worse than we anticipate, our existing cash reserves would be insufficient to repay the entire principal balance of the Financing Agreement or satisfy our liquidity needs. The presence of these projected factors in conjunction with the uncertainty of the capital markets raises substantial doubt about the Company's ability to continue as a going concern for the next twelve months from the issuance of these financial statements.

The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### Product portfolio

Our portfolio of products focused on women’s health allows us to efficiently leverage our sales and marketing plans to grow our pharmaceutical products. We are focused on activities necessary for the continued commercialization of IMVEXXY, commercially launched in the third quarter of 2018; BIJUVA, commercially launched in the third quarter of 2019; and ANNOVERA, which we started selling in the third quarter of 2019 and commercially launched in March 2020, which was subsequently paused as a result of the COVID-19 pandemic and relaunched in July 2020. We continue to manufacture and distribute our prescription prenatal vitamin product lines, consisting of branded prenatal vitamins under vitaMedMD and authorized generic formulations of some of our prescription prenatal vitamin products under BocaGreenMD.

#### ANNOVERA (segesterone acetate (“SA”) and ethinyl estradiol (“EE”) vaginal system)

This pharmaceutical product is a one-year, ring-shaped, contraceptive vaginal system (“CVS”) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year). ANNOVERA is commercially sold by us in the U.S. pursuant to the terms of the Population Council License Agreement. As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20.0 million, half of such excess will offset against royalties or other payments owed by us under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.

In August 2021, we filed a supplemental New Drug Application (“NDA”) with the FDA to modify the testing specifications for ANNOVERA to allow increased consistency of supply of ANNOVERA. In May 2022, the FDA approved the supplemental NDA for ANNOVERA. With the FDA approval of the supplemental NDA, we expect our third-party contract manufacturer will be able to supply us with sufficient ANNOVERA to better meet customer demand.

#### IMVEXXY (estradiol vaginal inserts), 4-μg and 10-μg

This pharmaceutical product is for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause. As part of the FDA’s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked two sponsors of other vaginal estrogen products to participate in an observational study. In connection with the observational study, we are required to provide various reports to the FDA per a requested timeline. We do not believe that the costs will be significant on an annual basis.

We market and sell IMVEXXY in the U.S. and have entered into licensing agreements with third parties to market and sell IMVEXXY outside of the U.S. We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which, we granted Knight an exclusive license to commercialize IMVEXXY in Canada and Israel. We have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY for human use outside of the U.S., except for Canada and Israel. As of September 30, 2022, no IMVEXXY sales have been made through these licensing agreements.

#### BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg

This pharmaceutical product is the first and only FDA approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. We market and sell BIJUVA in the U.S. and have entered into licensing agreements with third parties to market and sell BIJUVA outside of the U.S. We have entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize BIJUVA in Canada and Israel. We have entered into the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA for human use outside of the U.S., except for Canada and Israel. We recorded BIJUVA sales through the Theramex License Agreement of $0.4 million and $1.4 million for the three and nine months ended September 30, 2022, respectively, and $0.7 million for the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2022 and 2021, no BIJUVA sales were made through the Knight License Agreement.

#### Prenatal vitamin products

We manufacture and distribute our prescription prenatal vitamin product lines under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prena1 name. We will continue to support the vitaMedMD and BocaGreenMD products as they are important products to our core customers and help provide us with continued access to sell our women’s health portfolio.

### Results of operations

### Three months ended September 30, 2022 compared with three months ended September 30, 2021

*Revenue.* Our total revenue for the third quarter of 2022 was $20.9 million, a decrease of $4.5 million, or 17.7%, compared to the third quarter of 2021.

The following table sets forth our revenue during these periods (in thousands):

| Product revenue: | Three Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| ANNOVERA | $10,415 | $11,807 |
| IMVEXXY | 6,947 | 8,016 |
| BIJUVA | 2,663 | 3,298 |
| Prescription vitamin | 892 | 1,335 |
| Product revenue, net | 20,917 | 24,456 |
| License and service | — | 950 |
| Total revenue, net | $20,917 | $25,406 |

Our sales of ANNOVERA were $10.4 million for the third quarter of 2022, a decrease of $1.4 million, or 11.8%, compared to the third quarter of 2021. This decrease was primarily due to a 13.4% decrease in the average sale price due to fluctuations in constrains of variable consideration (product returns, chargebacks, rebates, coupons, discounts and wholesaler fees) on revenue, partially offset by a 1.9% increase in sales volume.

Our sales of IMVEXXY were $6.9 million for the third quarter of 2022, a decrease of $1.1 million, or 13.3%, compared to the third quarter of 2021. This decrease was primarily due to a 24.0% decrease in the average sale price due to fluctuations in revenue constraints, partially offset by a 14.0% increase in sales volume.

Our sales of BIJUVA were $2.7 million for the third quarter of 2022, a decrease of $0.6 million, or 19.3%, compared to the third quarter of 2021. Included in our BIJUVA sales for the third quarter of 2022 was $0.4 million of sales made through the Theramex License Agreement. Without the sales made through the Theramex License Agreement, our sales of BIJUVA were $2.3 million for the third quarter of 2022, a decrease of $0.3 million, or 11.2%, compared to the third quarter of 2021. This decrease was primarily attributable to a 16.6% decrease in the average sale price due to fluctuations in revenue constraints, partially offset by a 6.5% increase in sales volume.

Our prescription vitamin sales were $0.9 million for the third quarter of 2022, a decrease of $0.4 million, or 33.2%, compared to the third quarter of 2021. This decrease was primarily due to a 30.8% decrease in sales volume and 3.4% decrease in the average sale price due to fluctuations in revenue constraints.

On a consolidated basis, our total product sales were $20.9 million for the third quarter of 2022, a decrease of $3.5 million, or 14.5%, compared to the third quarter of 2021.

We recorded less than $0.1 million of service revenue related to pharmacy services provided by our vitaCare business to pharmaceutical companies for the third quarter of 2021 and no service revenue related to pharmacy services for the third quarter of 2022 due to our divesture of our vitaCare business earlier in 2022. We recorded no license revenue for the third quarter of 2022, and $0.9 million for the third quarter of 2021. This change in license revenue was entirely due to the timing of achieving previously established milestone payment targets.

*Gross profit.* Our gross profit for the third quarter of 2022 was $17.1 million, a decrease of $3.0 million, or 14.9%, compared to the third quarter of 2021. The following table sets forth our gross profit during these periods (in thousands):

|  | Three Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Product | $17,129 | $19,174 |
| License and service | - | 950 |
| Total gross profit | $17,129 | $20,124 |

The decrease in our gross profit was a result a decrease of 14.5% in product revenue for the third quarter of 2022, partially offset by an increase in our product gross margin of 3.5% to 81.9% for the third quarter of 2022. The increase in product gross margins was mainly due to changes in product sales mix during the third quarter of 2022.

*Operating expenses.* Total operating expenses for the third quarter of 2022 were $37.9 million, a decrease of $22.2 million, or 36.9%, compared to the third quarter of 2021. The decrease in operating expenses reflects our efforts to reduce operating expenses, including the reduction of vitaCare operating expenses in connection with its divestiture in April 2022.

The following table sets forth our operating expense categories (in thousands):

|  | Three Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Selling and marketing | $19,129 | $30,005 |
| General and administrative | 17,635 | 28,435 |
| Research and development | 1,112 | 1,605 |
| Total operating expenses | $37,876 | $60,045 |

Our selling and marketing costs were $19.1 million for the third quarter of 2022, a decrease of $10.9 million, or 36.2%, compared to the third quarter of 2021. This decrease was primarily due to $11.3 million in lower advertising and marketing expenses, $1.9 million in lower compensation and employee benefit costs, and $0.2 million in lower sales conference and travel expenses. These decreases were partially offset by $1.9 million in vitaCare service fee for the third quarter of 2022, $0.5 million in higher samples expense and $0.2 million in higher software development expenses.

Our general and administrative costs were $17.6 million for the third quarter of 2022, which included cash and accelerated equity severances amounting to $4.8 million for our former chief executive officer. Our general and administrative costs decreased $10.8 million, or 38.0%, compared to the third quarter of 2021, which included cash and accelerated equity severances amounting to $7.3 million for certain of our former senior executives. The overall decrease in general and administrative costs was primarily related to $9.2 million in lower compensation and employee benefit costs, $0.8 million in lower information technology expenditures, and $0.5 in lower corporate rent.

Our R&D costs were $1.1 million for the third quarter of 2022, a decrease of $0.5 million, or 30.7%, compared to the third quarter of 2021. This decrease was primarily attributable to $0.3 million in lower compensation and employee benefit costs and $0.2 million in lower lab research and sample testing costs. As we refocus our resources towards the continued commercialization of our pharmaceutical products, our R&D expenditures have declined over the last few years. We continue to deploy limited resources in the development of new products, to perform stability testing and validation on our pharmaceutical products, to develop and validate secondary manufacturers, to prepare regulatory submissions, and work with regulatory authorities on existing submissions.

*Loss from operations.* For the third quarter of 2022, we had a loss from operations of $20.7 million, a decrease of $19.2 million, or 48.0%, compared to the third quarter of 2021. This decrease was attributable to $22.2 million in lower operating expenses, partially offset by a $3.0 million in lower gross profit. We anticipate that we will continue to have operating losses for the near future until we are able to successfully commercialize ANNOVERA, IMVEXXY and BIJUVA, although there is no assurance that our efforts will be successful.

*Other income/expense, net.* For the third quarter of 2022, we had non-operating expense of $8.5 million, an increase of $1.0 million, or 13.1%, compared to the third quarter of 2021. This increase was primarily attributable to $3.5 million of expense for accretion of Series A Preferred Stock recorded for the third quarter of 2022 and $1.1 million in higher amortization of deferred financing costs compared to the third quarter of 2021. These increases were partially offset by $3.1 million in lower interest expense related to lower average debt balance and $0.7 million in lower interest prepayment fee due to elimination of prepayment fees with Amendment No. 9 to the Financing Agreement.

*Provision for income taxes.* For the third quarter of 2022, we recorded a reduction to provision for income taxes of $0.3 million compared to no provision for income taxes for the third quarter of 2022.

*Net loss.* For the third quarter of 2022, we had net loss of $29.0 million, or $3.13 per basic and diluted common share, compared to $47.4 million, or $5.62 per basic and diluted common share for the third quarter of 2021. The historical per share data have been adjusted to give effect of the May 2022 reverse stock split.

### Nine months ended September 30, 2022 compared with nine months ended September 30, 2021

*Revenue.* Our total revenue for the first nine months of 2022 was $68.8 million, an increase of $0.5 million, or 0.8%, compared to the first nine months of 2021.

The following table sets forth our revenue during these periods (in thousands):

| Product revenue: | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| ANNOVERA | $37,196 | $30,112 |
| IMVEXXY | 20,583 | 24,866 |
| BIJUVA | 7,877 | 7,899 |
| Prescription vitamin | 2,671 | 4,162 |
| Product revenue, net | 68,327 | 67,039 |
| License and service | 484 | 1,234 |
| Total revenue, net | $68,811 | $68,273 |

Our sales of ANNOVERA were $37.2 million for the first nine months of 2022, an increase of $7.1 million, or 23.5%, compared to the first nine months of 2021. This increase was primarily due to a 32.1% increase in sales volume, partially offset by a 6.5% decrease in the average sale price due to fluctuations in revenue constraints.

Our sales of IMVEXXY were $20.6 million for the first nine months of 2022, a decrease of $4.3 million, or 17.2%, compared to the first nine months of 2021. This decrease was primarily attributable to a 17.0% decrease in the average sales price due to fluctuations in revenue constraints and a 0.2% decrease in sales volume.

Our sales of BIJUVA were $7.9 million for the first nine months of 2022, which was flat when compared to the first nine months of 2021. Included in our BIJUVA sales for the first nine months of 2022 and 2021 was $1.4 million and $0.7 million, respectively, of sales made through the Theramex License Agreement. Without the sales made through the Theramex License Agreement, our sales of BIJUVA were $6.5 million for the first nine months of 2022, a decrease of $0.7 million, or 10.0%, compared to the first nine months of 2021. This decrease was primarily attributable to a 9.3% decrease in the average sale price due to fluctuations in revenue constraints and a 0.8% decrease in sales volume.

Our prescription vitamin sales were $2.7 million for the first nine months of 2022, a decrease of $1.5 million, or 35.8%, compared to the first nine months of 2021. This decrease was primarily due to a 28.1% decrease in sales volume and a 10.8% decrease in the average sale price due to fluctuations in revenue constraints.

On a consolidated basis, our total product sales were $68.3 million for the first nine months of 2022, an increase of $1.3 million, or 1.9%, compared to the first nine months of 2021.

We recorded service revenue related to pharmacy services provided by our vitaCare business to pharmaceutical companies of $0.5 million for the first nine months of 2022, an increase of $0.4 million, compared to the first nine months of 2021. We recorded no license revenue for the first nine months of 2022 and our license revenue was $1.2 million for the first nine months of 2021. This change in license revenue was entirely due to the timing of achieving previously established milestone payment targets.

*Gross profit.* Our gross profit for the first nine months of 2022 was $55.4 million, an increase of $1.3 million, or 2.3%, compared to the first nine months of 2021. The following table sets forth our gross profit during these periods (in thousands):

|  | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Product | $54,939 | $52,938 |
| License and service | 484 | 1,234 |
| Total gross profit | $55,423 | $54,172 |

26

The increase in our gross profit was a result an increase of 1.4% in our product gross margin to 80.4% and an increase of 1.9% in product revenue for the first nine months of 2022. The increase in product gross margins was mainly due to changes in product sales mix during the first nine months of 2022.

*Operating expenses.* Total operating expenses for the first nine months of 2022 were $121.2 million, a decrease of $37.3 million, or 23.5%, compared to the first nine months of 2021. The decrease in operating expenses reflects our efforts to reduce operating expenses, including the reduction of vitaCare operating expenses in connection with its divestiture in April 2022. The following table sets forth our operating expense categories (in thousands):

|  | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Selling and marketing | $61,703 | $86,193 |
| General and administrative | 55,445 | 66,691 |
| Research and development | 4,092 | 5,666 |
| Total operating expenses | $121,240 | $158,550 |

Our selling and marketing costs were $61.7 million for the first nine months of 2022, a decrease of $24.5 million, or 28.4%, compared to the first nine months of 2021. This decrease was primarily due to $27.3 million in lower advertising and marketing expenses and $2.4 million in lower compensation and employee benefit costs and consulting expenses. These decreases were partially offset by $3.5 million in vitaCare service fee recorded for the first nine months of 2022, $1.2 million in higher sales conference and travel expenses, and $0.7 million in higher software development expenses.

Our general and administrative costs were $55.4 million for the first nine months of 2022, a decrease of $11.2 million, or 16.9%, compared to the first nine months of 2021. This decrease was primarily related to $12.1 million in lower compensation and employee benefit costs, $2.7 million in lower information technology expenditures, $1.0 in lower corporate rent, and $0.4 million in lower investor relations expenses. These decreases were partially offset by $4.8 million in higher expenditures attributable to various professional fees, such as legal, consulting, etc.

Our R&D costs were $4.1 million for the first nine months of 2022, a decrease of $1.6 million, or 27.8%, compared to the first nine months of 2021. This decrease was primarily attributable to $1.3 million in lower compensation and employee benefit costs, partially offset by $0.2 million in higher lab research costs. As we refocus our resources towards the continued commercialization of our pharmaceutical products, our R&D expenditures have declined over the last few years. We continue to deploy limited resources in the development of new products, to perform stability testing and validation on our pharmaceutical products, to develop and validate secondary manufacturers, to prepare regulatory submissions, and work with regulatory authorities on existing submissions.

*Loss from operations.* For the first nine months of 2022, we had a loss from operations of $65.8 million, a decrease of $38.6 million, or 36.9%, compared to the first nine months of 2021. This decrease was attributable to $37.3 million in lower operating expenses and $1.3 million in higher gross profit. We anticipate that we will continue to have operating losses for the near future until we are able to successfully commercialize ANNOVERA, IMVEXXY and BIJUVA, although there is no assurance that our efforts will be successful.

*Other income/expense, net.* For the first nine months of 2022, we had non-operating income of $100.4 million compared to non-operating expense of $25.1 million for the first nine months of 2021. This $125.5 million positive change was primarily attributable to the $143.4 million gain on the sale of the vitaCare business, net of transaction costs, $6.3 million in lower interest expense related to lower debt balance, and $4.0 million in lower interest prepayment fee due to the elimination of prepayment fees with Amendment No. 9 to the Financing Agreement. These positive changes were partially offset by $15.9 million in higher amortization of deferred financing costs, and $8.4 million in loss on extinguishment of debt in connection with Amendment No. 9 to the Financing Agreement, which is recorded as an extinguishment of debt for accounting purposes, compared to the first nine months of 2021.

*Provision for income taxes.* For the first nine months of 2022, we recorded a provision for income taxes of $0.3 million compared to no provision for income taxes for the first nine months of 2021.

*Net loss/income.* For the first nine months of 2022, we had net income of $34.3 million, or $3.86 per basic common share and $3.73 per diluted common share. Our results for the first nine months of 2022 included a non-recurring gain on sale of business related to the vitaCare Divestiture of $143.0 million, net of taxes, or $16.12 per basic common share and $15.55 per diluted common share. Without the non-recurring gain, we would have had a net loss of $108.8 million, or $12.26 per basic and diluted common share, for the first nine months of 2022 compared to a net loss of $129.5 million, or $16.68 per basic and diluted common share, for the first nine months of 2021. The historical per share data have been adjusted to give effect to the May 2022 reverse stock split.

### Liquidity and capital resources

Our primary use of cash is to fund the continued commercialization of our hormone therapy and contraceptive products. We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities. As of September 30, 2022, we had cash totaling $27.1 million. We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. We have never experienced any losses related to these funds.

On April 14, 2022, we completed the vitaCare Divestiture and included $11.3 million of customary holdbacks, as provided in the Purchase Agreement, which is recorded as restricted cash in the consolidated balance sheets. The restricted cash is held by an escrow agent and will be released to us in April 2023 upon a joint written direction from the buyer and us being delivered to the escrow agent to disburse to us an amount equal to the amount of escrow funds less any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement. Any amounts subject to a claim notice in accordance with the terms set forth in the Purchase Agreement shall be retained by the escrow agent until each such claim subject thereto is resolved. Additionally, we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare’s financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement. We utilized $120.0 million of net proceeds from the vitaCare Divestiture to make a prepayment of the loans under the Financing Agreement under the terms of Amendment No. 9 of the Financing Agreement.

See “Going Concern” above for further discussion related to our ability to generate and obtain adequate amounts of cash to meet our liquidity needs and our plans for to satisfy our such needs in the short-term and in the long-term.

### Cash flows

The following table reflects the major categories of cash flows for each of the periods (in thousands).

|  | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(63,850) | $(103,135) |
| Net cash provided by (used in) investing activities | 142,316 | (709) |
| Net cash (used in) provided by financing activities | (105,258) | 128,199 |
| Net (decrease) increase in cash and restricted cash | $(26,792) | $24,355 |

*Operating Activities.* The principal use of cash in operating activities was to fund our current expenditures in support of our continued commercialization activities for ANNOVERA, IMVEXXY, and BIJUVA, sales, marketing, scale-up and manufacturing activities, adjusted for non-cash items. For the first nine months of 2022, net cash used in operating activities was $63.9 million, compared to net cash used in operating activities of $103.1 million for the first nine months of 2021. This decrease of $39.3 million, or 38.1%, was primarily due to a $124.5 million decrease in adjustments to reconcile net income (loss) to net cash used in operating activities, partially offset by a $163.8 million increase in our net income.

*Investing Activities.* For the first nine months of 2022, net cash provided by investing activities was $142.3 million, compared to net cash used in investing activities of $0.7 million for the first nine months of 2021. This increase of $143.0 million was primarily due to $142.6 million in proceeds from the 2022 sale of the vitaCare business, net of transaction costs, partially offset by lower patent related costs of $0.4 million, and lower fixed asset purchases.

*Financing Activities.* Financing activities have historically represented the principal source of our cash flow. For the first nine months of 2022, net cash used in financing activities was $105.3 million, compared to net cash provided by financing activities of $128.2 million for the first nine months of 2021. This negative change of $233.5 million was primarily related to $180.4 million in lower net proceeds from sales of our common stock and $75.0 million in higher repayment of debt. These negative changes were partially offset by $4.4 million in payments of debt financing fees in 2021, and $18.0 million in net proceeds from the sale of Series A Preferred Stock.

For additional details, see the consolidated statements of cash flows and Note 16, Subsequent events, in Item 1, Financial Statements, appearing elsewhere in this 10-Q Report.

### Other liquidity measures

*Receivable.* Our net days sales outstanding (“DSO”) is calculated by dividing average gross accounts receivable less the reserve for doubtful accounts, chargebacks, and payment discounts by the average daily net product revenue during the last four quarters for each respective quarterly period. Our net DSO was 145 days as of September 30, 2022, compared to 146 days as of December 31, 2021 and 125 days as of September 30, 2021. Our gross DSO is calculated by dividing average gross accounts receivable by the average daily gross product revenue to distributors during the last four quarters for each respective quarterly period. Our gross DSO was 65 days as of September 30, 2022, compared to 72 days as of December 31, 2021 and 61 days as of September 30, 2021. Our DSOs have fluctuated and will continue to fluctuate in the future due to variety of factors, including longer payment terms associated with the continued commercialization of ANNOVERA, IMVEXXY, and BIJUVA and changes in the healthcare industry. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.

*Inventory.* We rely on third parties to manufacture our finished products, and we have entered into long-term supply agreements for the manufacture of ANNOVERA, IMVEXXY, and BIJUVA. We do not have a long-term supply agreement for the manufacture of our prescription vitamins. Additionally, we do not have long-term contracts for the supply of all the active pharmaceutical ingredients used in ANNOVERA and BIJUVA. For additional information, see Note 3, Inventory in Item 1, Financial Statements, appearing elsewhere in this 10-Q Report.

*Debt.* We had $94.4 million and $200.0 million in term loans outstanding under our Financing Agreement as of September 30, 2022 and December 31, 2021, respectively. For additional information, see Note 8, Debt and Note 16, Subsequent events, in Item 1, Financial Statements, appearing elsewhere in this 10-Q Report.

### Contractual obligations, off-balance sheet arrangements and purchase commitments and employment agreements

Except for entering into Amendment No. 9 to the Financing Agreement in March 2022, Amendments 10 and 11 to the Financing Agreement in May 2022, Amendments 12 through 16 to the Financing Agreement in July 2022, make whole payments we owe to the Preferred Stock Investor under the Subscription Agreements we entered into in July, September and October 2022, and the long-term services agreement with vitaCare, which we are required to pay a minimum service fee for each respective annual contract year, there were no other material changes from December 31, 2021 to September 30, 2022. Our estimated minimum service fee commitments for vitaCare are as follows: $2.0 million for the period from October 1, 2022 to December 31, 2022, $10.7 million for 2023, $13.4 million for 2024, $15.4 million for 2025, $16.2 million for 2026, and $5.5 million for the period from January 1, 2027 to April 14, 2027. See Note 10 – Mandatory Redeemable Preferred Stock and Stockholders’ Deficit for additional information regarding the equity financing with the Preferred Stock Investor. For discussion on amendments to the Financing Agreement, see Note 8, Debt and Note 16, Subsequent events, in Item 1, Financial Statements, appearing elsewhere in this 10-Q Report. For a discussion of matters in this section, refer to Item 7 - Contractual obligations, off-balance sheet arrangements and purchase commitments and employment agreements of our 2021 10-K Report.

### Critical accounting policies and estimates

Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included elsewhere in this 10‑Q Report, which has been prepared in accordance with U.S. GAAP. We make estimates and assumptions that affect the reported amounts on our consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. The critical accounting policies and estimates used are disclosed in Item 7 - Critical accounting policies and estimates in our 2021 10-K Report.

## Market risk

As filed, 244 characters.

As a “smaller reporting company,” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Instruction 6 to Item 201(e) of Regulation S-K, we are not required to provide this information.

## Controls and procedures

As filed, 2,954 characters.

### Management’s evaluation of disclosure controls and procedures

#### Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions regarding required disclosure.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officers and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this 10-Q Report. Based on that evaluation, our Chief Executive Officers and Interim Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this 10-Q Report were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officers and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, including our Chief Executive Officers and Interim Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.

### Changes in internal controls over financing reporting

There were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the three months ended September 30, 2022.

## Risk factors

As filed, 7,472 characters.

The business, financial condition and operating results of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of the 2021 10-K Report under the heading “Risk Factors,” any one or more of which could, directly or indirectly, cause the Company’s actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition, operating results and stock price. Except as set forth below, there have been no material changes to the Company’s risk factors since the 2021 10-K Report.

***Our level of indebtedness and other liabilities, and the terms of the Financing Agreement, which matures in November 2022, raise substantial doubt about our ability to continue as a going concern.***

Our substantial amount of indebtedness and other liabilities could adversely affect our business. As of September 30, 2022, we had $94.4 million of debt outstanding under the Financing Agreement. In addition, in the third quarter of 2022, we issued 22 thousand shares of our newly-designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) and we issued an additional seven thousand shares of Series A Preferred Stock in October 2022. The Series A Preferred Stock has a liquidation preference equal to $1,333 per share of Series A Preferred Stock and matures on December 31, 2022, subject to certain extension terms, as set forth in the Certificate of Designation, Preferences and Rights of Series A Preferred Stock (the “Certificate of Designation”), and the Company is required to redeem the shares on such date at a redemption price per share of Series A Preferred Stock, payable in cash, equal to the liquidation preference. In addition, we have incurred make-whole payments we owe to Rubric Capital Management LP under the Subscription Agreements pursuant to which the Series A Preferred Stock was issued.

Our high level of indebtedness and other liabilities could affect our business in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt and other liabilities; limit management’s discretion in operating our business; and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy.

The Financing Agreement contains a minimum unrestricted cash balance requirement and several other restrictive covenants. The Financing Agreement requires that we and our subsidiaries party to the Financing Agreement must maintain a minimum unrestricted cash balance of $10.0 million. The Financing Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the Financing Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, and (vii) enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. To maintain compliance with the minimum unrestricted cash balance requirement of the Financing Agreement, we anticipate that we may need to raise additional capital. We cannot guarantee that future financing sufficient to maintain or exceed the minimum unrestricted cash balance will be available in sufficient amounts, in a timely fashion, or on terms acceptable to us, if at all. If we are unable to maintain the minimum unrestricted cash balance or otherwise comply with any other covenant of the Financing Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which would have an adverse effect on our business, results of operations and financial condition.

In addition, our Financing Agreement matures on November 30, 2022, and the entire principal balance under the Financing Agreement is due and payable as of such date. Our current cash on hand is not sufficient to pay the amounts due under the Financing Agreement. This raises substantial doubt about our ability to continue as a going concern. We will need to raise additional capital to repay the entire principal balance of the Financing Agreement upon maturity. The report of our independent registered public accounting firm on our audited financial statements contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our audited financial statements as of and for the year ended December 31, 2021 and our unaudited financial statements as of and for the three and nine months ended September 30, 2022 do not include any adjustments that might result from the outcome of the uncertainty regarding our ability to continue as a going concern. This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity or debt securities or otherwise. Further, we currently have approximately 1.1 million shares of Common Stock available to be issued under our current authorization, which limits our ability to raise capital through equity financing. In addition, the Certificate of Designation establishing the powers, designations, preferences and privileges and the qualifications, limitations or restrictions of our Series A Preferred Stock contains restrictions that could limit our ability to raise more capital, including a prohibition on incurring certain indebtedness or liens. If we cannot continue as a going concern, our investors may lose their entire investment in our securities. Until we can generate significant cash flows, we expect to satisfy our future cash needs through debt or equity financing; however, there can be no assurance that such capital will be available, or if available, that it will be on terms acceptable to us.

If we are unable raise additional capital or to generate cash flow through operations, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt, or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including under the Financing Agreement.

Filed Nov 14, 2022.
Source: SEC EDGAR, the filing index for accession 0001564590-22-037666. Last ingested by Listed: Nov 14, 2026, 19:24 ET. No prices; not investment advice.
